Alexion stock rises on reports of activist investor – Stock in the US rare disease specialist Alexion Pharmaceuticals is up 6% this morning on reports that the famed New York-based activist hedge fund Elliot Management has taken a stake. Elliott has reportedly threatened to initiate a proxy battle potentially to replace the relatively new management team […]
FDA OK for Alexion’s Soliris in myasthenia gravis US approval for Alexion’s complement inhibitor Soliris in anti-acetylcholine receptor antibody-positive generalised myasthenia gravis could double the market for a product that is already selling $3bn/year, if some of the most optimistic sell-siders are to be believed. Soliris, which is famously one of, if not the, most […]
Biotech Growth manager denies allegations – The board of The Biotech Growth Trust says that it notes that the General Partners of OrbiMed Capital LLC, which acts as portfolio manager to the company, released a statement late on 5 December concerning founding partner Samuel Isaly, who is the subject of a press article containing allegations of […]
BioPharma secures second deal for up to $200m – BioPharma Credit PLC has announced that it and BioPharma Credit Investments IV, S.àr.L., entered into a definitive term loan agreement for up to US$200 million with Lexicon Pharmaceuticals, Inc. (NASDAQ: LXRX), a fully integrated biopharmaceutical company with a current market capitalisation of approximately US$1.0bn. Lexicon markets XERMELO® (teloristat […]
BioPharma Credit makes first major investment since IPO – BioPharma Credit PLC says that, on 21 November 2017, it and BioPharma Credit Investments IV, S.àr.L.entered into a definitive loan agreement for up to US$500 million with TESARO, Inc. (NASDAQ: TSRO), a oncology focused biopharmaceutical company with a market capitalisation of US$4.5 billion. TESARO has commercial […]
International Biotechnology beats benchmark on strong listed portfolio performance – In the year ended 31 August 2017, International Biotechnology Trust’s NAV rose from 575.1p to 672.9p, including a significant currency gain, equivalent to 14.4 pence per share. The NAV returned 20.9% in. Over the same period, the Shareholders total return was 30.5%. This compares to a rise […]
Biotech Growth lags benchmark but shareholders still make 28%. Biotech Growth says that it produced a good return in absolute terms for the year ended 31 March 2017. The net asset value per share rose by 27.5% during the year, which compares with the benchmark, the NASDAQ Biotechnology Index (sterling adjusted), which rose by 29.2%. As […]
Please review our cookie, privacy & data protection and terms and conditions policies and, if you accept, please select your place of residence and whether you are a private or professional investor.
Due to data protection policies, USA residents can not access our data.
Your content has been curated